AR060598A1 - Derivados de anilino-pirimidina inhibidores de proteinquinasas de la ruta nf-kb - Google Patents
Derivados de anilino-pirimidina inhibidores de proteinquinasas de la ruta nf-kbInfo
- Publication number
- AR060598A1 AR060598A1 ARP070101544A ARP070101544A AR060598A1 AR 060598 A1 AR060598 A1 AR 060598A1 AR P070101544 A ARP070101544 A AR P070101544A AR P070101544 A ARP070101544 A AR P070101544A AR 060598 A1 AR060598 A1 AR 060598A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- heteroatoms
- alkyl
- hydrogen
- Prior art date
Links
- 150000008059 anilinopyrimidines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 3
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical class CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 abstract 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 guanidinyl Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) caracterizado porque: R2 se selecciona del grupo que consiste de -NR7R8, guanidinilo, ureido, imidazolilo opcionalmente sustituido, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, hidroxi alcoxi; R3 se selecciona del grupo que consiste de un fenilo opcionalmente sustituido, un tienilo opcionalmente sustituido, un pirazinilo opcionalmente sustituido, un pirrolilo opcionalmente sustituido, un grupo naftilo, biciclo[2.2.1]hepteno, un benzotiofeno opcionalmente sustituido, un indol opcionalmente sustituido y un benzofurano opcionalmente sustituido, en donde los anillos se pueden opcionalmente interrumpir por un grupo C=O; R5 se selecciona del grupo que consiste de hidrogeno, metilo, alquilo, alquilcarbonilo, alcoxicarbonilo; R6 se selecciona del grupo que consiste de hidrogeno; halogeno; fenilo opcionalmente sustituido; un anillo heteroarilo de 5 o 6 miembros opcionalmente sustituido con 1 a 4 heteroátomos; un anillo de benceno fusionado un anillo de 0 a 4 heteroátomos, interumpido por 0 a 2 de los grupos C=O, SO, o SO2, y opcionalmente sustituido; un anillo monocíclico, o policíclico opcionalmente sustituido que contiene 0 a 4 heteroátomos; -NR7R8; -COOR9; -CONR7R8; y -SO2R10, alquilo opcionalmente sustituido alquenilo opcionalmente sustituido; alquinilo opcionalmente sustituido; hidroxi; alcoxi; OR7; y SR7; R7 y R8 se seleccionan independientemente dle grupo que consiste de hidrogeno; alquilo opcionalmente sustituido; alquenilo opcionalmente sustituido; alquinilo opcionalmente sustituido; arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; hidroxi; alcoxi; alquilamino; arilamino; heteroarilamino; - NCOR9; -COR9; -CONR7R8; SO2R10; aminas cíclicas de 3 a 10 miembros opcionalmente sustituidas que contienen de 0 a 3 heteroátomos; opcionalmente, R7 y R8 juntos forman un anillo monocíclico o bicíclico de 3 a 12 miembros opcionalmente sustituido que contienen de 0 a 4 heteroátomos; R9 se selecciona del grupo que consiste de hidrogeno, metilo, trifluorometilo, alquilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R10 se selecciona del grupo que consiste de metilo, tri-fluorometilo, alquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido y NR7R8; y sales y solvatos e hidratos de estos. Composiciones farmacéuticas que los contienen y usos como agentes antiinflamarotios y anticancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79171606P | 2006-04-12 | 2006-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060598A1 true AR060598A1 (es) | 2008-07-02 |
Family
ID=38458255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101544A AR060598A1 (es) | 2006-04-12 | 2007-04-11 | Derivados de anilino-pirimidina inhibidores de proteinquinasas de la ruta nf-kb |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070244140A1 (es) |
| EP (1) | EP2004638A1 (es) |
| CN (1) | CN101460491A (es) |
| AR (1) | AR060598A1 (es) |
| AU (1) | AU2007238897A1 (es) |
| BR (1) | BRPI0709949A2 (es) |
| CA (1) | CA2649302A1 (es) |
| MX (1) | MX2008013203A (es) |
| PE (1) | PE20080185A1 (es) |
| TW (1) | TW200812978A (es) |
| WO (1) | WO2007120593A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7279288B2 (en) * | 2004-09-03 | 2007-10-09 | California Institute Of Technology | I kappa B kinase complex as a target for the treatment of Huntington's disease |
| JP4891111B2 (ja) * | 2007-02-16 | 2012-03-07 | 富士フイルム株式会社 | ズームレンズ |
| CL2008000835A1 (es) | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| DK3126351T3 (en) * | 2014-04-02 | 2019-01-14 | Bristol Myers Squibb Co | BIARYLKINASE INHIBITORS |
| PT4421069T (pt) | 2014-10-13 | 2026-01-12 | Yuhan Corp | Compostos e composições para modular atividades da cinase do egfr mutante |
| WO2017059080A1 (en) * | 2015-10-01 | 2017-04-06 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| US11110078B2 (en) | 2018-03-29 | 2021-09-07 | Amrita Vishwa Vidyapeetham | Composition and method for treatment of diseases associated with central nervous system inflammation |
| CN109438365B (zh) * | 2018-12-06 | 2022-04-05 | 华南师范大学 | N-(3-((4-三氟甲基)-2-嘧啶基)氨基苯基)-2,6-二氟苯磺酰胺衍生物 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN115197203B (zh) * | 2021-04-12 | 2024-06-25 | 上海医药工业研究院 | 苯胺嘧啶类化合物、其制备方法及应用 |
| CN114014847B (zh) * | 2021-12-08 | 2023-11-03 | 滨州医学院 | 一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551735A (en) * | 1983-05-30 | 1985-11-05 | Canon Kabushiki Kaisha | Ink jet recording apparatus |
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| WO2002079197A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US7348335B2 (en) * | 2002-11-05 | 2008-03-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| DE602004024374D1 (de) * | 2003-03-13 | 2010-01-14 | Vertex Pharma | Zusammensetzungen zur verwendung als protein-kinase-inhibitoren |
| RU2007114080A (ru) * | 2004-10-13 | 2008-11-27 | Вайет (Us) | N-бензилсульфонил-замещенные аналоги анилинопиримидина |
| GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| US7803806B2 (en) * | 2005-11-03 | 2010-09-28 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
-
2007
- 2007-04-09 AU AU2007238897A patent/AU2007238897A1/en not_active Abandoned
- 2007-04-09 EP EP07755094A patent/EP2004638A1/en not_active Withdrawn
- 2007-04-09 MX MX2008013203A patent/MX2008013203A/es unknown
- 2007-04-09 CN CNA2007800201460A patent/CN101460491A/zh active Pending
- 2007-04-09 WO PCT/US2007/008709 patent/WO2007120593A1/en not_active Ceased
- 2007-04-09 CA CA002649302A patent/CA2649302A1/en not_active Abandoned
- 2007-04-09 BR BRPI0709949-5A patent/BRPI0709949A2/pt not_active Application Discontinuation
- 2007-04-10 US US11/786,380 patent/US20070244140A1/en not_active Abandoned
- 2007-04-11 AR ARP070101544A patent/AR060598A1/es unknown
- 2007-04-11 PE PE2007000441A patent/PE20080185A1/es not_active Application Discontinuation
- 2007-04-12 TW TW096112873A patent/TW200812978A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101460491A (zh) | 2009-06-17 |
| AU2007238897A1 (en) | 2007-10-25 |
| BRPI0709949A2 (pt) | 2011-08-30 |
| US20070244140A1 (en) | 2007-10-18 |
| TW200812978A (en) | 2008-03-16 |
| MX2008013203A (es) | 2008-10-22 |
| WO2007120593A1 (en) | 2007-10-25 |
| EP2004638A1 (en) | 2008-12-24 |
| PE20080185A1 (es) | 2008-02-24 |
| CA2649302A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060598A1 (es) | Derivados de anilino-pirimidina inhibidores de proteinquinasas de la ruta nf-kb | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR076002A1 (es) | Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR077362A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| AR072726A1 (es) | Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c | |
| AR114240A1 (es) | Antranilamidas, su uso como insecticida y procesos para su preparación | |
| AR063147A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central. | |
| CO5601021A2 (es) | Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb | |
| ECSP10010380A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
| AR046170A1 (es) | Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b | |
| AR062405A1 (es) | Derivados de isoindol | |
| AR089853A1 (es) | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso | |
| AR066873A1 (es) | Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas | |
| AR036074A1 (es) | Derivados de aminoquinolina, las composiciones farmaceuticas que los contienen, el uso de los mismos para la preparacion de una composicion farmaceutica, un procedimiento para su preparacion y los intermediarios empleados en dicho procedimiento de preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |